Please select the option that best describes you:
Would you recommend Radium-223 for extensive bone disease in a prostate cancer patient with adenopathy >3cm?
Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxel.
Answer from: Radiation Oncologist at Academic Institution
I think that there are several nuances to this question. One, Xofigo is a calcium mimetic which has shown both overall survival advantage as well as improvement in symptomatic skeletal events for men who progressed on docetaxel or refused chemotherapy in the ALSYMPCA trial. Patients expe...
Sign in or Register to read more